cancer research campaign uk charity signed deal us pharmaceuticals company develop pioneering cancer treatment could earn charity much pounds 20m year the drug called temozolomide first effective treatment glioma form braintumour cancer research funded research development drug originally discovered aston university birmingham further clinical trials establish drugs effectiveness forms cancer set professor edward newlands head cancer medicine charing cross westminster medical school director drugs clinical trials said may prove effective bone marrow cancer the agreement scheringplough largest ever concluded charitys whollyowned technology transfer company worth immediate dollars 15m dollars 4m paid charity development once drug launched charity receive royalty payments these could worth pounds 20m year according dr sue foden managing director cancer research campaign technology charitys technology transfer subsidiary last year charitys income raised mainly voluntary contributions pounds 406m under agreement charity receive 40 per cent royalties worth 2 per cent 8 per cent sales depending volume the remaining 60 per cent royalties paid rhonepoulenc rorer francoamerican company helped initial research aston university discovered molecule charing cross westminster medical school developed professor newlands explained half glioma patients using drug shown clinical benefit many 40 per cent demonstrated improvement examined brainscans patients skin cancer also shown improvement he said first time drug repeatable noteworthy effect brain tumours the charity said hoped scheringplough would able use us food drug administrations accelerated licensing programme medicine would american market within five years the potential market temozolomide difficult predict depended whether worked cancers professor newlands said